Yet they behave differently once they enter your system, and those differences matter when you pick a plan
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
We challenge the notion of treating obesity, discuss its benefits, and how our current healthcare system lacks support for behavioral change
223,224 GLP-1 also inhibits glucagon release from -cells, which is beneficial for reducing blood glucose levels since glucagon promotes hepatic gluconeogenesis
Blood test markers to discuss with a clinician Marker IGF-1 Why it matters Provides IGF-axis context, although interpretation can be complex with IGF analog exposure
Multiple sessions allow gradual sculpting for a natural jawline
.png)
